Director Bernadette Connaughton sold Halozyme Therapeutics ($HALO) shares eight times on the open market over the past year, for a total of about $782 thousand. Her latest sale occurred on January 5, 2026. These transactions rank 5,466th out of nearly 12,000 insiders, trailing the average sale value of $8.6 million across 6.4 transactions per insider. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 5, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Director | S | Common Stock | 2000 | $70.25 | 40,123.0000 | 123,904,000 | 4.75% | 0.00% |
| Dec. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Director | S | Common Stock | 829 | $71.60 | 42,123.0000 | 124,449,000 | 1.93% | 0.00% |
| Nov. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Director | S | Common Stock | 2000 | $68.48 | 42,952.0000 | 124,449,000 | 4.45% | 0.00% |
| Oct. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Not found | S | Common Stock | 1500 | $75.09 | 45,452.0000 | 124,449,000 | 3.19% | 0.00% |
| Oct. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Not found | S | Common Stock | 500 | $75.70 | 44,952.0000 | 124,449,000 | 1.10% | 0.00% |
| Sept. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Not found | S | Common Stock | 2977 | $73.62 | 47,875.0000 | 129,424,000 | 5.85% | 0.00% |
| Sept. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Not found | S | Common Stock | 100 | $71.71 | 50,852.0000 | 129,424,000 | 0.20% | 0.00% |
| Sept. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Not found | S | Common Stock | 923 | $74.11 | 46,952.0000 | 129,424,000 | 1.93% | 0.00% |
| June 6, 2025 | Editas Medicine, Inc. | $EDIT | Connaughton Bernadette | Director | A | Stock Option (right to buy) | 37500 | $0.00 | 37,500.0000 | 82,976,284 | 9999.99% | 0.05% |
| May 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Not found | A | Option to Purchase Common Stock | 5750 | $0.00 | 5,750.0000 | 129,424,000 | 9999.99% | 0.00% |
| May 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Not found | A | Common Stock | 4165 | $0.00 | 50,952.0000 | 129,424,000 | 8.90% | 0.00% |
| May 30, 2024 | Editas Medicine, Inc. | $EDIT | Connaughton Bernadette | Director | A | Stock Option (right to buy) | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |
| April 25, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Not found | A | Option to Purchase Common Stock | 8804 | $0.00 | 8,804.0000 | 134,197,000 | 9999.99% | 0.01% |
| April 25, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Connaughton Bernadette | Not found | A | Common Stock | 6501 | $0.00 | 46,787.0000 | 134,197,000 | 16.14% | 0.00% |
| June 1, 2023 | Editas Medicine, Inc. | $EDIT | Connaughton Bernadette | Not found | A | Stock Option (right to buy) | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |